|
Balance Sheet Cash Flow Statement 5420 Feltl Rd. Minnetonka, MN 55343 MN Tel. 952-426-6140 Fax 952-426-6199 |
Type: Public
On the web:
http://www.uroplasty.com
Employees:
68
Employee growth: 7.9%
Uroplasty makes implants used primarily to treat urinary incontinence and overactive bladder. Its flagship product is Macroplastique, a soft-tissue bulking material for the treatment of urinary incontinence, that is injected during a minimally invasive outpatient procedure. Another minimally invasive device, the Urgent PC, uses electrical pulses to treat overactive bladder symptoms. Uroplasty's I-Stop Mid-Urethral Sling treats female incontinence. The company also sells soft-tissue bulking agents used in plastic surgery, vocal cord rehabilitation, and treatment of fecal incontinence. Uroplasty markets its products primarily in Europe and the US; it won FDA approval to market Macroplastique in 2006.
Key numbers for fiscal year ending March, 2009:
Sales: $14.7M
One year growth: 6.4%
Net income: ($3.6)M
Officers:
Chairman: R. Patrick Maxwell
President, CEO, and Director: David B. Kaysen
COO and Secretary: Susan Hartjes Holman
Competitors:
Boston Scientific
Bard
Medtronic
